Anthracycline drugs are widely used for the treatment of solid tumors and leukemia, but the molecular basis of their biological eect is still poorly understood. In the HCT 116 colon carcinoma cell line, which retains a wildtype inducible p53 gene, we show that the anthracycline daunomycin is a potent inducer of p53 and NF-kB transcription factors. Nuclear accumulation of p53 protein occurred because of increased protein stability and enhanced gene expression. In addition, daunomycin induced the p53 promoter through the binding of p50/p65 NF-kB heterodimers to the kB site in the p53 promoter. Under our conditions, the free radical scavengers NAC and PDTC were not able to block NF-kB activation or p53 induction, indicating that reactive oxygen intermediates were not involved in the cellular response to daunomycin stimulation. Overexpression of a stable unresponsive IkBa mutant in HCT116 cells resulted in a complete inhibition of the NF-kB activation but only a partial impairment of the p53 protein accumulation induced by daunomycin. We conclude that the p53-activating signal generated by daunomycin is partially regulated by NF-kB.
Introduction
New drugs and new chemotherapeutical approaches are continuously being developed for the treatment of cancer. Anthracycline drugs are widely used in the treatment of many neoplasic diseases, but the molecular basis of their biological eects is still poorly understood. Their toxicity is generally thought to be the result of drug-induced DNA damage. The mechanisms responsible for this damage to the DNA can involve the generation of free radicals, the intercalation-induced distorsion of the double helix, or the stabilization of the cleavable complex formed between DNA and topoisomerase II (Tewey et al., 1984; Doroshow, 1986) . The interaction of these drugs with their intracellular targets leads to a modi®ed expression of tumor suppressor genes and transcription factors involved in cell growth control.
The tumor suppressor gene p53 is one of the most frequently mutated genes in human malignancies (for reviews see Hollstein et al., 1991; Levine et al., 1991; Vogelstein and Kinzler, 1992) . A role for p53 in normal cellular proliferation has not been clearly identi®ed. However, there is abundant evidence that wild-type p53 plays a critical role in the cellular response to DNA damage by controlling a cell cycle checkpoint that is important for maintaining the integrity of the genome (Hartwell, 1992; Lane, 1992) . p53 levels increase in cells exposed to DNA damaging agents such as U.V. light, g irradiation and anticancer drugs (Maltzman and Czyzyk, 1984; Fritsche et al., 1993) . The cells then undergo a cell cycle arrest or delay in the G1 phase allowing the repair of DNA damage. p53-dependent G1 arrest appears to be mediated by p21/WAF1 (Bae et al., 1995; Brugaloras et al., 1995; Deng et al., 1995) , a cyclin-dependent kinase inhibitor whose gene is transcriptionally activated by p53 (El-Deiry et al., 1993; Harper et al., 1993) . p53 also plays a role in the signaling of apoptosis (programed cell death) following irradiation (Abrahamson et al., 1995; Lowe et al., 1996) .
Human p53 is a 393-amino acid nuclear phosphoprotein, functioning as a transcription factor. It contains an oligomerization domain in its carboxyl terminus, a speci®c DNA binding domain in the center portion of the molecule, and a transactivation domain in the amino terminus (Lane, 1992; El-Deiry et al., 1992) . Wild-type but not mutant p53 has also been shown to bind speci®c DNA sequences and induce transcriptional activation of target genes containing p53 binding sites (Farmer et al., 1992; Fields and Jang, 1990; Kern et al., 1991 Kern et al., , 1992 Smith et al., 1994; Miyashita et al., 1994) . Several genes activated by p53 have been identi®ed. These genes include Gadd45, which stimulates DNA repair (Smith et al., 1994) , Bcl-2 family members which play critical roles in apoptosis (Miyashita et al., 1994) , p21/WAF1, mdm2 and the p53 gene itself . Transcriptional regulation of the p53 gene occurs through both promoter and exon sequences (Reisman and Rotter, 1989; Tuck and Crawford, 1989) . The human p53 promoter lacks a TATA box and contains three transcriptional start sites as well as potential binding motifs for heat shock factors (Abravaya et al., 1991) , helix ± loop ± helix transcription factors (Ronen et al., 1991) and for p53 itself (Dee et al., 1993) . The sequence of this p53 responsive element is almost identical to a Nuclear Factor-kB (NF-kB) binding site.
NF-kB is a rapidly inducible transcription factor involved in the response of various cell types to a number of external or internal stimuli. Following its intracellular activation, NF-kB regulates the expression of many genes which code for cytokines, growth factors, acute phase response proteins and cellular receptors and thus modulates the cellular response to the stimulus. Several viruses such as the Human Immunode®ciency Virus type-1 (HIV-1) or the cytomegalovirus also depend on NF-kB for their intracellullar replication (see recent reviews for a complete list of NF-kB-dependent genes and viruses: Baeuerle and Henkel, 1994; Siebenlist et al., 1994; Miyamoto and Verma, 1995) .
NF-kB complexes bind DNA as dimers constituted from a family of proteins designated as the Rel/NF-kB family. In mammals, this family contains the proteins p50, p52, p65 (RelA), RelB and c-Rel (Rel) (Baeuerle and Henkel, 1994; Siebenlist et al., 1994; Miyamoto and Verma, 1995) . These ®ve proteins harbor a related, but nonidentical, 300 amino acid long Rel homology domain (RelHD) which is responsible for dimerization, nuclear translocation and speci®c DNA-binding. In addition, p65, RelB and c-Rel, but not p50 and p52, contain one or two transactivating domains. p50 and p52 derive from cytoplasmic precursors designated p105 and p100, respectively.
NF-kB complexes are sequestered in the cytoplasm of most resting cells by inhibitory proteins belonging to the IkB family. The members of the IkB family are IkBa, IkBb, IkBe, p100 and p105 (Haskill et al., 1991; Beg and Baldwin, 1993; Mercurio et al., 1993; Rice et al., 1992; Thompson et al., 1995; Whiteside et al., 1997) . Bcl-3 also belongs to this family but, at least in some cellular types, is nuclear and participates in NFkB transactivating activity (Bours et al., 1993; Franzoso et al., 1992; Nolan et al., 1993; Ohno et al., 1990) .
Following various stimuli, including the interaction of TNF-a and IL-1b with their receptors, IkBa is ®rst phosphorylated on serines 32 and 36 and then rapidly degraded by the proteasome, allowing NF-kB nuclear translocation and gene activation (Osborn et al., 1989; Beg et al., 1993; Brown et al., 1993 Brown et al., , 1995 Palombella et al., 1994; Traenckner et al., 1995) . The signal transduction pathways leading to the phosphorylation and degradation of IkB proteins are still poorly understood and even quite controversial. It has been reported that any stimulus activating NF-kB, including TNF-a and IL-1b, proceeds through the intracellular production of free radicals and reactive oxygen intermediates (ROIs) (Schreck et al., 1991 (Schreck et al., , 1992 . We have demonstrated NF-kB activation following IL-1b stimulation in human transformed epithelial cell lines. In these cells, contrary to lymphoid cell lines, IL-1b-mediated induction of NF-kB does not proceed through the production of reactive oxygen intermediates (ROIs) (Bonizzi et al., 1996) . Other reports have recently shown that NF-kB is also activated by DNA damaging agents such as photosensitizers or topoisomerase poisons Piret and Piette, 1996) .
The presence of an NF-kB binding site in the promoter element of the p53 gene raised the possibility that NF-kB regulates the expression of the p53 gene. Recent reports have shown that TNF-a-induced NFkB can stimulate the transcription of the murine p53 promoter (Wu and Lozano, 1994) . Another report indicated that while NF-kB is inducible by genotoxic agents such as U.V. light or anticancer drugs, it does not play a major role in human p53 promoter activation induced by genotoxic agents (Sun et al., 1995) . In this work, we have investigated the nuclear induction of the transcriptional factors NF-kB and p53 by the daunomycin drug. We demonstrate a transcriptional activation of human and murine p53 promoters by drug-induced NF-kB complexes in colorectal cancer cells. However, inhibition of NF-kB translocation by stable transfection of an unresponsive IkBa mutant resulted only in a faint decrease in the p53 protein accumulation induced by daunomycin.
Results

Enhanced p53 expression in HCT 116 cells treated by daunomycin
In order to investigate the mechanisms leading to p53 protein accumulation in human colon carcinoma cells after a genotoxic stress, the HCT 116 cells which retain a wild-type inducible p53 gene were treated with daunomycin for increasing periods of time. Western blotting performed with nuclear protein extracts and revealed with an anti-p53 monoclonal antibody showed an increased p53 nuclear expression following stimulation of HCT116 cells with daunomycin at 1 mM ( Figure  1a ). p53 expression reached its maximum after 6 h of treatment (Figure 1a ), remained increased up to 24 h, and was still detectable in surviving cells for at least (PDTC) or N-acetylcysteine (NAC) treatment on p53 induction by daunomycin. HCT116 cells were pretreated with PDTC at 60 mM or with NAC at 10 mM for 1 h. Then daunomycin (1 mM) was added and nuclear extracts were prepared after 2, 4 or 6 h of daunomycin treatment in the presence of the antioxidants. 10 mg of proteins was analysed by Western blotting. On this blot, a nonspeci®c band is observed with all cell extracts just above the speci®c p53 band. This nonspeci®c band was also observed on longer exposures of the blots shown in a and b 72 h (data not shown). No p53 protein was detectable in untreated cells ( Figure 1a , lane 0). It has previously been reported that p53 protein accumulation following DNA damage was mainly due to an increased stability of the protein (Finlay et al., 1988) . Therefore, the stability of the daunomycin-induced p53 protein was evaluated by treating HCT116 cells with cycloheximide 16 h after the beginning of the daunomycin incubation. Under these conditions, the p53 protein appeared to be highly stable, as the signal observed on immunoblots did not decrease after a 2 ± 6 h cycloheximide (CHX) incubation (Figure 1b ). This high stability is signi®cantly longer than the reported short half-life of wild-type p53 (Reich and Levine, 1984) and thus probably participates in the nuclear accumulation of p53 in daunomycin-treated HCT116 cells.
Anthracycline drugs intercalate into DNA bases and induce topoisomerase II-dependent DNA strand breaks. The putative agents responsible for this druginduced DNA damage have been suggested to be superoxide radical, hydrogen peroxide or hydroxyl radical. We thus investigated whether the drugdependent p53 induction was mediated by free radicals. The free radical scavengers N-acetylcysteine (NAC, 10 mM) and pyrrolidine-9-dithiocarbamate (PDTC, 30 mM) as well as higher concentrations of PDTC (120 mM) did not block p53 activation in daunomycin-stimulated cells ( Figure 1c ). These results suggest that p53 induction in HCT116 cells is not mediated by intracellular free radicals.
To study whether the p53 protein accumulation in drug-treated cells was associated with an increase in p53-speci®c RNA expression, we isolated total cellular RNA from drug-treated HCT116 cells at dierent times after treatment. Northern blotting (Figure 2 ) demonstrated that the treated cells exhibited a 2 ± 3-fold increase in the p53-speci®c mRNA. This induction was quanti®ed by densitometry on the autoradiographies (data not shown) and demonstrates that p53 response to daunomycin stress in HCT 116 cells is partially regulated at the mRNA level.
Induction of NF-kB by daunomycin in HCT 116 cells
As shown by other authors, the human p53 promoter region contains potential binding motifs for heat shock factor (Abravaya et al., 1991) , NF-kB (Yamamoto et al., 1992) and helix ± loop ± helix transcription factors (Ronen et al., 1991) . To determine whether NF-kB proteins are involved in daunomycin-induced p53 expression, we ®rst examined the induction of NF-kB complexes in drug-treated colon carcinoma cells. Electrophoretic Mobility Shift Assays (EMSA) performed with nuclear extracts from HCT116 cells showed that stimulation with daunomycin at 1 mM induced a strong NF-kB DNA binding activity, which reached its maximum after 3 h of treatment. This induction was observed when the nuclear extracts were incubated with a speci®c palindromic kB probe (data not shown) or with a probe derived from nucleotides +45 to +68 of the p53 ®rst exon (Figure 3a) . Incubation with cycloheximide did not inhibit and even prolonged NF-kB activation by daunomycin. Under our experimental conditions, two speci®c bands were visible on the autoradiographies: an intense upper band and a fainter and faster migrating band. Supershifting experiments performed with antibodies directed toward NF-kB proteins demonstrated that the upper band, which was displaced by both p50 and p65 antibodies, was formed mainly of p50/p65 heterodimers, while the lower band, which reacted only with p50 antibodies, probably corresponded to p50 homodimers (Figure 3b ). Thus, NF-kB present in nuclear extracts from daunomycin-induced HCT116 cells bound speci®cally to the kB site from the p53 promoter. This binding was unaected by the preincubation with free radical scavengers NAC (data not shown) or PDTC (Figure 3c ). However, the p50 homodimer-DNA complex was considerably fainter in cells preincubated with PDTC than in control cells. It is thus possible that antioxidants inhibited the faint induction of the p50 homodimers without aecting the activation of the p50/p65 transactivating complexes.
To further investigate the mechanism for NF-kB activation by daunomycin, we studied the reactivity of various NF-kB inhibitors to the applied stimulus. We ®rst con®rmed that daunomycin treatment led to a degradation of the IkBa protein as observed on immunoblots performed with HCT116 cytoplasmic extracts (Figure 4) . The extracts were obtained from the same cells as those whose nuclear extracts were used in the EMSA experiments. The kinetics of IkBa degradation paralleled NF-kB translocation to the nucleus. IkBa was still present on the immunoblots in signi®cant amounts 1 h after the stimulus; after 6 h, most of the IkBa protein was decayed although a faint band was still visible. Interestingly, daunomycin did not induce any detectable degradation of p100 ( Figure  4) , p105 or IkBb (data not shown) inhibitors in the same cells. These results suggest that daunomycininduced NFkB activation is mainly regulated by IkBa degradation.
NF-kB regulation of the p53 promoter
Since p50/p65 NF-kB heterodimers bind the p53 promoter, we investigated whether these daunomycininduced complexes could trancriptionally regulate the HCT116 cells were treated with daunomycin at 1 mM for 3 or 6 h with or without a pretreatment with CHX at 25 mg/ml for 1 h. Total cellular RNAs (15 mg) were analysed by Northern blotting and hybridized to human p53 cDNA; the same blot was washed and rehybridized to a b-actin cDNA probe p53 gene promoter. We ®rst examined the inducibility of the p53 promoter in daunomycin-treated HCT 116 cells. The p0.5CAT reporter plasmid containing 500 bp of the p53 murine promoter and the pM5CAT construct containing the same promoter mutated at the kB site (Wu and Lozano, 1994) were transfected in HCT116 cells, and CAT activities were measured after exposure to daunomycin. As shown in Figure 5a , 1 mM of daunomycin was able to induce the p53 promoterdriven CAT gene expression 2 ± 3-fold above the control level. Under the same conditions, transfection of the pM5CAT construct did not generate any increase in the CAT activity after incubation with daunomycin, indicating that the kB site was required for the responsiveness to this genotoxic stress. These data were reproduced with higher daunomycin concentrations (2 and 3 mM) (data not shown).
In separate experiments, each of these reporter plasmids was transfected together with expression vectors directing the production of various NF-kBrelated proteins. As shown in Figure 5a , the murine p53 promoter was signi®cantly transactivated 2 ± 10-fold by NF-kB p65 expression vector. The mutant promoter pM5CAT was not responsive to the expression of p65, indicating that p65 activated the murine p53 promoter through the NF-kB site. The expression of p50 in addition to p65 reduced the activation of the p53 promoter as compared to p65 alone (data not shown). The expression of c-Rel also transactivated the murine promoter (3 ± 7-fold above control level, data not shown). IκB-α Figure 4 Eect of daunomycin on NF-kB inhibitors. HCT116 cells were treated with 1 mM daunomycin for the indicated times. Cytoplasmic protein extracts (10 mg) were analysed by Western blotting using a polyclonal IkBa speci®c antibody or a p100/p52 monoclonal antibody. Arrows indicate the position of the speci®c bands p65 transactivation eciency was also studied with the human promoter p53LUC constructs (Stuart et al., 1995) which contained 550 base pairs of the human p53 promoter, including the sequence of exon 1 cloned upstream of the luciferase reporter gene. As observed with the murine p53 promoter, daunomycin and p65 stimulated transcription through the human promoter (Figure 5b ).
Stable expression of mutated IkBa in HCT116 cells
In order to examine whether NF-kB activation was required for p53 accumulation after daunomycin treatment, NF-kB nuclear translocation was inhibited by stable transfection of a dominant-negative IkBa mutant in HCT 116 cells. Indeed, the substitution of Ser-32 and Ser-36 by alanine residues in the IkBa Nterminal domain made this mutant resistant to both phosphorylation and proteolytic degradation and thus completely blocked NF-kB activation (Brown et al., 1995; Traenckner et al., 1995; Whiteside et al., 1995) .
The clones stably transfected with the vector expressing the mutated IkBa gene (MT9 cells) were ®rst screened for protein expression by Western blotting. EMSA analysis demonstrated that the expression of the IkBa mutant (MT9 cells) led to a complete suppression of daunomycin-induced NF-kB activation ( Figure 6 ). In addition the same MT9 cells did not show any nuclear induction of the NF-kB transcription factor after TNF-a or IL-1b stimulation (data not shown), thus indicating a complete inhibition of the NF-kB activating pathway.
In transient transfection assays, daunomycin stimulation or NF-kB p65 expression in MT9 cells did not induce signi®cant p53 promoter activation as compared with the level of transactivation in the control cells ( Figure 7 , compare with Figure 5b ). These data provide direct evidence that the functional inhibition of NF-kB alters the daunomycin-induced p53 promoter activation in transient transfection assays and support the view that daunomycin-mediated p53 transcription is NF-kB-dependent.
However, Western blotting revealed only a faint decrease in p53 nuclear accumulation in daunomycin- Figure 5 Daunomycin and NF-kB regulation of the p53 promoter. (a) HCT 116 cells were cotransfected with the wildtype murine p53 promoter (p0.5CAT) (1 mg) or with the mutated pM5CAT (1 mg) and p65 expression plasmid at increasing concentrations. Twenty-four hours after plasmid reporter transfection, cells were treated for 6 h with 1 mM daunomycin before determination of CAT activity. CAT activity is expressed in fold induction relative to the uninduced value obtained with the reporter plasmid alone arbitrarily set to 1.0. Each value represents the mean of a minimum of three independent experiments after normalization to the protein concentration of the extracts. (b) HCT 116 cells were cotransfected with the human p53 promoter p53LUC construct (0.5 mg) and with increasing amounts of the p65 expression plasmid. Alternatively, 24 h after reporter plasmid transfection, daunomycin was added at increasing concentrations. After 6 h of incubation, cells were harvested and LUC activity was measured in a luminometer. LUC activity is expressed in fold induction relative to the activity observed with the LUC reporter plasmid alone. Each value represents the mean of a minimum of three independent experiments after normalization to the protein concentration of the extracts C 0 3 6
Dauno (h) Figure 6 Inhibition of NF-kB activation in cells expressing the mutant IkBa. HCT116 cells stably transfected with the IkBa unresponsive mutant (HCT116MT9) were treated with daunomycin for the indicated times. Nuclear protein extracts (5 mg) were analysed by EMSA using a labeled probe corresponding to the kB site of the human p53 promoter. The arrows indicate the speci®c NF-kB complexes p50/p50 (white arrowhead) and p50/p65 (black arrowhead). Lane C refers to control HCT116 cells treated with daunomycin for 6 h induced MT9 cells expressing the IkBa mutant as compared to control cells (Figure 8 ). Moreover, there was no signi®cant dierence in p53 mRNA levels (Northern blot) between cells expressing the mutant IkBa and control cells (data not shown). These results indicate that NF-kB is not an essential requirement for p53 protein accumulation.
Discussion
The treatment of neoplasia with radiation or chemotherapy results in extensive DNA damage and activates the p53 signaling pathway. In untreated HCT 116 colorectal cells, the p53 wild-type protein is kept at a low and undetectable concentration probably because of its short half-life (about 20 min). Here, we have reported that daunomycin is a potent inducer of p53 and NF-kB transcription factors in these cells. The activation of p53 in response to daunomycin was manifested by the increased levels of the p53 mRNA and p53 protein. In addition, we have shown that daunomycin induced the p53 promoter through the binding of p50/p65 heterodimers to the kB site. The p65 subunit of NF-kB activated both human and murine p53 promoters in transient tranfection assays. Overexpression of mutated IkBa in HCT116 cells completely inhibited NF-kB activation and p53 promoter transactivation induced by daunomycin and p65 expression. Previous studies reported by Wu and Lozano (1994) in Hela cells have identi®ed the murine p53 responsive element which overlaps with an NF-kB binding site. This kB site is responsible for the induction of p53 transcription by TNF-a and transfected p65. These results are in disagreement with those reported by Sun et al. (1995) showing that NF-kB, while inducible by various anticancer drugs such as mitomycin and 5-uorouracil, does not play a major role in human p53 promoter activation induced by genotoxic agents. We demonstrated in this paper that, in human colorectal cells, both murine and human p53 promoters were activated by NF-kB after exposure to the anticancer drug daunomycin. This apparent discrepancy could result either from the promoter constructs, since Sun et al. (1995) used a shorter human p53 promoter sequence, or from the lack of essential cellular factors. Indeed, another report had previously shown that daunomycin failed to trigger p53 gene expression in myeloid leukemia cells, indicating that anthracycline drugs might have distinct p53 induction activities in dierent cell types (Nelson and Kastan, 1994) .
In our experiments, p53 mRNA levels were increased (2 ± 3-fold) after treatment of cells with daunomycin. Under the same conditions, the degree of p53 protein induction was more than threefold, and we showed that daunomycin induced an increase in p53 protein stability. These results suggest that the p53 response to daunomycin is regulated at the protein level as well as the mRNA level.
The mechanism by which DNA damage causes a stabilization of the p53 remains unclear and could involve a repression of the ubiquitin-mediated degradation pathway, modi®cations of the p53 phosphorylation status, or a redox regulation (Maki and Howley, 1997; Meek, 1994; Hainaut and Milner, 1993a,b; Hainaut et al., 1995a,b) .
The drug-induced p53 protein may either inhibit cell growth, allowing the DNA repair process, or initiate apoptosis (Lowe et al., 1993 (Lowe et al., , 1996 . The p53-dependent G1 arrest appears to be mediated by p21 (Bae et al., 1995; Brugaloras et al., 1995; Deng et al., 1995) , a cyclin-dependent kinase inhibitor whose gene is transcriptionally activated by p53 (El-Deiry et al., 1993; Harper et al., 1993) . Under our experimental conditions, we observed a daunomycin-induced expression of p21/WAF1 protein (data not shown).
The NF-kB heterodimer consisting of p50 and p65 polypeptides was induced by daunomycin in HCT116 cells. A similar observation had previously been Figure 7 Inhibition of daunomycin-induced p53 promoter transactivation in cells expressing the mutant IkBa. HCT116 MT9 cells stably expressing the mutant IkBa protein were transfected with the human p53 promoter p53LUC reporter plasmid (0.5 mg) and with increasing amounts of the p65 expression plasmid. Alternatively, 24 h after reporter plasmid transfection, daunomycin was added at increasing concentrations for 6 h. LUC activity was measured in a luminometer and is expressed as fold induction relative to the activity observed with the LUC reporter plasmid alone. Each value represents the mean of a minimum of three independent experiments after normalization to the protein concentration of the extracts ) were treated with daunomycin at 1 mM for the indicated times. Nuclear protein extracts (10 mg) were analysed by Western blotting using an anti-p53 monoclonal antibody reported by Piret and Piette (1996) in T lymphocytic cells. These authors proposed that DNA strand breaks generated by daunomycin can lead to the activation of NF-kB. We have shown by EMSA that this activation was not inhibited by cycloheximide, indicating that daunomycin-induced NF-kB activation did not involve protein synthesis. The ability of antioxidants to inhibit NF-kB activation following treatment with daunomycin was analysed and, under our experimental conditions, the free radical scavengers NAC and PDTC were not able to block daunomycin-induced NF-kB activation and p53 induction, suggesting that ROIs were not involved. Moreover, we recently demonstrated that the activation of NF-kB in IL-1b-stimulated epithelial cells was also ROI-independent and probably relied on the activation of the acid sphingomyelinase and the concomitant generation of ceramide (Bonizzi et al., 1996; Bonizzi et al., unpublished results) . Recent studies (Bose et al., 1995; JareÂ zou et al., 1996) demonstrated daunomycin-stimulated ceramide production and apoptosis in leukemia cells via activation of the ceramide synthase or the neutral sphingomyelinase. Although further experiments are needed to fully characterize the mechanisms of activation of NF-kB and p53 in daunomycin-treated cells, these observations suggest a ceramide-dependent, ROI-independent pathway.
The transcription factors AP1, NF-kB and ATF2 are activated upon exposure of mammalian cells to U.V. irradiation (Devary et al., 1993; Sachsenmaier et al., 1994) . Although there is a putative AP-1 site in the p53 promoter, no transcriptional regulation of the p53 promoter by AP-1 has been observed (Ginsberg et al., 1990) . NF-kB is the only transcription factor identi®ed so far that regulates p53 expression while also being regulated by U.V. irradiation.
Another common inducer of NF-kB and p53 is TNF-a, a multifunctional cytokine that mediates various in¯ammatory and cellular immune responses. TNF-a induces the nuclear translocation of NF-kB by phosphorylation and dissociation of IkBa from the NF-kB complex (Beg et al., 1993) . Wu and Lozano (1994) showed that, in HeLa cells, TNF-a activates the p53 promoter through the NF-kB site.
In this study, we have shown that the endogenous IkBa is degraded as a consequence of daunomycin treatment. As a result, NF-kB translocates to the nucleus, where it participates in the activation of p53 gene transcription. We stably transfected HCT116 cells with a cDNA coding for a mutated IkBa that is resistant to both phosphorylation and proteolytic degradation and thus behaves as a potent dominantnegative IkBa protein. In transfected cells, the daunomycin-induced NF-kB activation was blocked and this inhibition completely altered the p53 promoter transactivation in transient transfection assays. However, the p53 protein accumulation induced by daunomycin was only faintly decreased by the inhibition of NF-kB in mutant IkBa cell lines, and mRNA induction was still observed. Several hypotheses could explain such an apparent discrepancy. First, endogenous wild-type IkBa in the mutant-transfected cell lines could be degraded following daunomycin treatment and thus lead to NF-kB activation despite the expression of the mutant IkBa. However, we could not observe any NF-kB activation in nuclear extracts from transfected cells. It could also be possible that, in HCT 116 cells, the observed transcriptional activation in transient transfections plays only a minor role in the increase in mRNA and protein levels. The increase in RNA expression could as well result from an increased mRNA stability. Alternatively, NF-kB independent regulatory sequences located outside of the promoter sequences cloned in the reporter plasmids could regulate p53 gene transcription. Other studies are required in order to con®rm the function of NF-kB in p53 activation in dierent cell types.
Materials and methods
Recombinant plasmids
p0.5CAT contains 500 bp of the murine p53 promoter including 320 bp of the promoter and 210 bp of exon 1 in front of the CAT gene. pM5CAT is identical to p0.5CAT except that it contains base pair mutations in the NF-kB site at positions +56 to +58 and +64 to +66. These plasmids were kindly provided by Wu and Lozano (1994) . p53LUC, which contains a 550 bp genomic fragment comprising the human p53 promoter and exon 1 in front of the luciferase gene, was constructed by Stuart et al. (1995) .
The expression vector pMT2T encoding the p65 NF-kB subunit was cloned by Bours et al. (1992) . Expression vectors pcRc-CMV (Invitrogen) encoding wild-type and mutant IkBa were obtained from Dr A IsraeÈ l (Institut Pasteur, Paris, France) (Whiteside et al., 1995) .
Cell culture and tranfection
HCT116 human colon carcinoma cells (ATCC CCL 247) were grown in McCoy's 5A modi®ed medium supplemented with 1% L-glutamine and 10% (v/v) fetal bovine serum (FCS, Life Technologies, Grand Island NY, USA). For induction with daunomycin, cells were cultured and exposed to the drug (1 mM) for various times under serum-starved conditions (2% FCS). N-acetylcysteine (NAC, 10 mM), pyrrolidone-9-dithiocarbamate (PDTC, 30, 60 and 120 mM, Sigma) and cycloheximide (CHX, 25 mg/ml) were added to the medium 60 min before daunomycin and were maintained during drug treatment.
For DNA transfection, cells were plated at a density of 5610 6 cells per 35 mm-diameter six-well culture dishes. Twenty-four hours later, the cells were transfected by the lipofection technique using cationic vesicles (DOTAP, Boehringer, Mannheim, Germany) at 15 mg with various amounts of p53-CAT reporter constructs and NF-kB expression vectors. The total amount of transfected DNA was kept constant by addition of parental pMT2T expression vector. Twenty-four hours after transfection, cells were treated for 6 h with daunomycin and then harvested for determination of CAT or LUC activities.
For stable transfections, 5610 6 HCT116 cells were plated in 35 mm dishes and were transfected with 5 mg of linearized plasmid. Twenty-four hours later, the cells were transferred to medium containing G418 (geneticin, 0.5 mg/ml active concentration). After approximately 4 weeks, G418-resistant colonies were selected and each of the resistant cloned cell lines examined by Western blotting.
Reporter plasmid assays
CAT activities were determined by the diusion assay as described by Neumann et al. (1987) . The cells were washed once in phosphate-buered saline and resuspended in 0.1 M Tris-HCl (pH 7.8) in order to be disrupted by three freeze-thawing cycles. The CAT activities were expressed as initial rates of chloramphenicol acetylation and were normalized to the protein amount quanti®ed by the Micro BCA Protein Assay Reagent (Pierce, Rockford, USA). Luciferase activities were determined by the Luciferase Reporter gene assay kit (Boehringer, Mannheim, Germany) as recommended by the manufacturer. Cells were lysed in the buer provided by the kit and LUC activities, as measured in a luminometer, were normalized to the protein concentration of the extracts.
Antibodies
The polyclonal anti-IkBa and anti-IkBb antibodies, the p100/p52 monoclonal antibody, the antipeptide antibody directed against an amino-terminal peptide of p50, and the antipeptide antibody directed against the N-terminal 14 amino acids following the initiator methionine of p65 were kindly provided by Dr Siebenlist (National Institute of Health, Bethesda, USA). Anti-RelB and anti-p105 antipeptide antibodies were purchased from Santa Cruz Biotechnology, Santa Cruz, USA. The c-Rel antipeptide antibody was obtained from Dr N Rice (NCI, Frederick, MD, USA). Human p53 was detected with monoclonal antibody pAb 1801 (Ab2, Oncogene Science, USA).
Protein extraction
Nuclear and cytoplasmic protein extracts were prepared as previously described by Dejardin et al. (1995) . Cytoplasmic buer contained 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES pH 7.9), 0.1 mM EDTA, 2 mM MgCl 2 , 10 mM KCl, 0.2% NP-40 and protease inhibitors (protease inhibitor kit, Boehringer, Germany). The pelleted nuclei were resuspended in nuclear buer (20 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.63 M NaCl, 25% glycerol, protease inhibitors), incubated for 20 min at 48C, and centrifuged for 30 min at 14 000 r.p.m. Protein amounts were quanti®ed with the Micro BCA Protein Assay Reagent (Pierce, Rockford, USA).
Electrophoretic mobility shift assays (EMSA)
Electrophoretic Mobility Shift Assays (EMSA) and supershifting analyses were performed as described (Bonizzi et al., 1996) . The palindromic (PD)-kB probe was 5'-TTG-GCAACGGCAGGGGAATTCCCCTCTCCTTAGGTT-3'. For supershifting experiments, 1 ml of the antibody was preincubated at 48C with the extracts for 30 min before addition of the labeled kB probe.
Oligonucleotides containing the kB site from the p53 promoter or the mutated site were also used for EMSA (5'-TTGGTGGGATTGGGACTTTCCCCT-3' and 5'-TTG-GTGGGATTATCACTTTCCCCT-3').
Western blotting
Protein extracts (10 mg) were run on a 10% SDS ± PAGE gel. After transfer to a nylon membrane (PVDF, Millipore) and blocking overnight with TBS-T buer plus 5% dry milk, the membranes were incubated for 1 h with the ®rst antibody, washed and then incubated for 1 h with the second peroxidase-conjugated antibody. The reaction was revealed with the enhanced chemoluminescence detection method (ECL kit, Amersham, UK).
Northern blotting
Total cellular RNA was prepared by the TriPure TM isolation reagent (Boehringer, Mannheim, Germany) according to the manufacturer's recommendation. The reagent (1 ml for 5610 6 cells) was directly added to the cells. 15 mg of RNA from each sample was electrophoresed on a 1.2% agarose-formaldehyde gel and transferred to a nylon membrane. A p53 probe containing the human p53 cDNA (Oncogene Science, USA) was 32 P labelled by random priming and hybridized to the blot. A b-actin cDNA probe was later used to rehybridize the same blot. Levels of p53 mRNA were quanti®ed with a densitometer and normalized to b-actin values.
